Q-VANT Biosciences, Inc.
Developer and manufacturer of saponin-based vaccine adjuvants. Provides scalable purification and supply of high-purity saponin fractions using a proprietary platform, supports vaccine formulation and preclinical evaluation, and offers regulatory and quality-dossier support for human and veterinary vaccine programs. Operations include manufacturing and R&D sites in the United States and Chile and collaborations with academic and industry partners.
Industries
N/A
Nr. of Employees
small (1-50)
Q-VANT Biosciences, Inc.
3 Haleys Way, Forestdale 02644, USA; El Ventisquero 1111, Of. 48, Renca, Santiago, Chile; Santa Victoria, B lot, Los Angeles, Chile
Products
High-purity QS-21 saponin adjuvant (lyophilized research-grade)
HPLC-verified, high-purity QS-21 saponin fraction provided as a lyophilized powder for research and preclinical studies; characterized for cellular and humoral potentiation.
Veterinary saponin adjuvant fractions for animal vaccines
Second-generation saponin adjuvant fractions intended for veterinary use (low-dose, potency for antibody and T-cell responses) with samples available for animal trials via distribution partners.
High-purity QS-21 saponin adjuvant (lyophilized research-grade)
HPLC-verified, high-purity QS-21 saponin fraction provided as a lyophilized powder for research and preclinical studies; characterized for cellular and humoral potentiation.
Veterinary saponin adjuvant fractions for animal vaccines
Second-generation saponin adjuvant fractions intended for veterinary use (low-dose, potency for antibody and T-cell responses) with samples available for animal trials via distribution partners.
Services
Advisory and hands-on support for formulating saponin adjuvants with antigens for research, preclinical and development-stage programs.
Provision of research-grade, high-purity saponin fractions through partnered distributors for preclinical testing.
Preparation of audit-ready regulatory dossiers and quality management documentation aligned to GMP requirements for adjuvant integration into vaccine programs.
Collaboration on academic and industry research projects, including participation in grant-funded initiatives and consortia.
Advisory and hands-on support for formulating saponin adjuvants with antigens for research, preclinical and development-stage programs.
Provision of research-grade, high-purity saponin fractions through partnered distributors for preclinical testing.
Preparation of audit-ready regulatory dossiers and quality management documentation aligned to GMP requirements for adjuvant integration into vaccine programs.
Collaboration on academic and industry research projects, including participation in grant-funded initiatives and consortia.
Expertise Areas
- Saponin adjuvant development
- Vaccine formulation and preclinical evaluation
- Adjuvant manufacturing and scale-up
- Supply chain and sustainable biomass sourcing
Key Technologies
- Multi-step chromatographic purification
- HPLC and LC-MS/MS analytical methods
- Lyophilized powder formulation
- Plant biomass sourcing and plant cell culture biomass
News & Updates
Announcement that a new state-of-the-art manufacturing facility is ready to start production.
Collaboration and NIH-funded project to develop an oral saponin-based dmLT adjuvant for mucosal vaccine delivery.
Strategic partnership announced to broaden access to pharma-grade saponin adjuvants, including partner investment and sample distribution arrangements.
Agreement signed for development and supply of Quillaja plant cell culture biomass to enhance sustainable supply.
Announcement that a new state-of-the-art manufacturing facility is ready to start production.
Collaboration and NIH-funded project to develop an oral saponin-based dmLT adjuvant for mucosal vaccine delivery.
Strategic partnership announced to broaden access to pharma-grade saponin adjuvants, including partner investment and sample distribution arrangements.
Agreement signed for development and supply of Quillaja plant cell culture biomass to enhance sustainable supply.